不安定性アンギナにおける犯人病変の血管活性
P Bogaty1, D Hackett, G Davies
1Cardiovascular Research Unit, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.
Circulation
|July 1, 1994
まとめ
不安定性アンギナの原因となる病変は,挑発的な検査で安定性アンギナ病変よりも著しく収縮する. この異常な血管活性は,再発性急性イシュケミアの兆候または予備因子となる可能性があります.
科学分野:
- 心臓病学 心臓病学
- 血管生物学 血管生物学
- 発血性心臓病 発血性心臓病 発血性心臓病 発血性心臓病とは
背景:
- 異常な血管収縮は,急性冠動脈症候群に関連しています.
- 不安定なアンギナ・カルプター病変の血管活性については,まだ調査されていない.
- 強化された血管活性が加害者の病変を超えて広がっているかどうかは不明です.
研究 の 目的:
- 不安定性アンギナにおける罪悪者の病変の血管活性性を調査する.
- 原因病変の血管活性と安定したアンギナ病変を比較するために.
- 遠心動脈および無関心動脈における血管活性性を評価する.
主な方法:
- 定量冠動脈血管撮影は,不安定性アンギナ患者7名と安定性アンギナ患者7名で実施した.
- 挑発的な刺激には,体力学的な自転車運動と冷圧器のテストが含まれていた.
- 犯人病変のルミナル直径,ディスタルセグメント,および関与していない動脈を測定しました.
主要な成果:
- 不安定性アンギナの原因となる病変は,運動と冷圧検査によって著しく縮小した.
- カルピット病変の直径は運動によって1.41mmから1.09mmに減少した (P=.001).
- 安定したアンギナコントロールの病変は,挑発的な刺激で直径の有意な変化を示さなかった.
結論:
- 安定したアンギナ病変と比較して,不安定なアンギナ・カルプター病変は血管活性性が増加しています.
- 関与していないまたは遠隔の冠動脈部分では,有意な血管活性が観察されなかった.
- 原因の病変部位における異常な血管活性が,再発性イシュケミアの兆候または予備因子となる可能性があります.
関連する概念動画
Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Angina II: Classification
Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
Angina III: Clinical Manifestations and Assessment
Angina manifests as chest pain, tightness, or squeezing discomfort typically located behind the breastbone. It can radiate to the neck, jaw, shoulders, and inner aspects of the upper arms, most commonly the left arm. Patients may experience shortness of breath, fatigue, profuse sweating, dizziness, indigestion, heartburn, palpitations, anxiety, and vomiting as accompanying symptoms. This pain often lasts a few minutes and is triggered by physical exertion, emotional stress, heavy meals, or cold...
Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Angina V: Nursing Management
Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...


